ArticleEuropean journal of dentistry2026
Osteogenic Marker Expression after SHED and PMMA-HA Scaffold Application in Alveolar Bone Defects.
Article in European journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objective: Alveolar bone defects in dentistry-caused by trauma, congenital anomalies, and periodontal disease-can substantially impair oral health and tooth function. These effects pose significant challenges in dentistry, and current gold-standard treatments such as autogenous bone grafting have notable limitations. Stem cell from human exfoliated deciduous teeth (SHED) has great potential for bone tissue engineering. The aim of this study was to evaluate the effect of SHED seeded in polymethylmethacrylate (PMMA)-hydroxyapatite (HA) scaffolds on the expression of osteogenic markers in alveolar bone defects. Materials and Methods: A total of 24 male Wistar rats had their maxillary incisors extracted, and the resulting defects were randomly assigned to three groups: (1) no treatment (control), (2) defects treated with PMMA-HA, and (3) defects treated with SHED seeded in PMMA-HA scaffolds. Immunoreactivity of BMP2, RUNX2, ALP, TGF-β, OCN, OPG, RANK, and RANKL was assessed. Results: Immunohistochemical results showed upregulated expression of BMP2, RUNX2, ALP, TGF-β, OCN, and OPG and downregulated expression of RANK and RANKL in rats treated with SHED-seeded PMMA-HA scaffolds compared with control and defects treated with PMMA-HA only groups. Conclusion: SHED seeded into PMMA-HA scaffolds effectively influenced the expression of several osteogenic markers, such as BMP2, RUNX2, ALP, TGF-β, OCN, OPG, RANK, and RANKL, in alveolar bone defects. These findings indicate that the combination of SHED and PMMA-HA scaffolds could potentially become a promising regenerative alternative to autogenous bone grafting in alveolar bone defects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.